Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
8
result(s) for
"Fahs, Barbara"
Sort by:
Exhibition as Dance: An Exercise in Creative Partnering
Similar to dance, exhibitions must be carefully choreographed. Determining the structural, visual, and rhythmic embodiment of the message is the critical design issue. Here, Charles looks at the development of three museum exhibitions from the perspective of the designer. She provides several examples, which are all biographical that address the creative process of partnering and finding the intellectual and creative structures that give physical shape to ideas, focus those ideas to meet the goals of the organizers, and present them in an engaging manner to the visitor.
Journal Article
Healing herbs : how to grow, store, and maximize their medicinal power
\"Dig into the world of herbal medicine with this complete guide to cultivating and harvesting plants with healing properties. For thousands of years, people have been utilizing herbs and cultivating weeds found to speed the healing of wounds, soothe skin irritations, calm uneasy stomachs, and ward off illnesses. In these pages, you'll learn the basics of gardening in your backyard or on your windowsill or porch. You'll also find profiles of useful herbs that are easy to grow or wildcraft, along with inspiring stories, medicine-making instructions, and recipes for your home medicine chest. Known to boost immunity, reduce blood pressure, aid digestion, and relieve arthritis among other medicinal properties, powerful plants such as garlic, Echinacea, yarrow, elderflower, mint, elecampane, and many more are included in this illustrated guide.\"--provided by publisher.
Book
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy 1 (PROMISE-1) study was a phase III, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, tolerability, and pharmacokinetic properties of repeat intravenous (IV) doses of the calcitonin gene–related peptide‒targeted monoclonal antibody eptinezumab (ALD403) for migraine prevention in adults with episodic migraine. Here we present the results of PROMISE-1 through 1 year of treatment (up to 4 doses).
Patients received up to 4 IV administrations of eptinezumab 30 mg, 100 mg, 300 mg, or placebo every 12 weeks. Patients recorded migraine and headache in an electronic diary daily. Additional assessments, including the patient-reported outcomes, were performed at regularly scheduled clinic visits throughout the 56-week study period.
A total of 888 adults (mean age, 39.8 years; 84.3% female; 83.8% white) received treatment: eptinezumab 30 mg, n = 219; eptinezumab 100 mg, n = 223; eptinezumab 300 mg, n = 224; and placebo, n = 222. During the primary 12-week study evaluation period, single doses of eptinezumab 100 mg and 300 mg led to significant reductions in mean monthly migraine-days versus placebo, beginning as early as the first day after the initial dose. The reduction in mean monthly migraine-days was maintained throughout the study (100 mg, −3.9, −4.5, −4.7, and −4.5 days; 300 mg, −4.3, −4.8, −5.1, and −5.3 days; and placebo, −3.2, −3.8, −4.0, and −4.0 days during weeks 1–12, 13–24, 25–36, and 37–48, respectively). Overall, the number of patients with a ≥50% or ≥75% reduction in migraine for each 12-week interval during the entire study was consistently numerically higher in the eptinezumab groups than in the placebo group. The proportions of patients with ≥50% reduction in migraine were similar across the eptinezumab groups. Eptinezumab was well tolerated throughout the study. Adverse events were similar across dosing periods, and there were no serious tolerability signals identified with continued dosing.
IV eptinezumab administered every 12 weeks for up to 4 doses was associated with early and sustained migraine-preventive effects and a favorable safety profile in adults with episodic migraine. ClinicalTrials.gov identifier: NCT02559895.
Journal Article
Use of the Term Cost Effective
To the Editor:
Although it was welcome, the Occasional Notes article on the misuse of the term \"cost effective\" (Jan. 23 issue)* has to some extent added to the confusion by presenting a definition different from that commonly applied by economists, at least on this side of the Atlantic. The authors rightly criticize the use of the term to mean either \"cost saving\" or \"effective.\" In their subsequent argument, however, they fail to distinguish between two forms of economic evaluation: cost-effectiveness analysis and cost–benefit analysis.
The distinction that economists draw between these relates directly to definitions 3 and 4 as . . .
No extract is available for articles shorter than 400 words.
Journal Article